ATE315567T1 - A-1-adenosin rezeptor antagoniste - Google Patents

A-1-adenosin rezeptor antagoniste

Info

Publication number
ATE315567T1
ATE315567T1 AT97947567T AT97947567T ATE315567T1 AT E315567 T1 ATE315567 T1 AT E315567T1 AT 97947567 T AT97947567 T AT 97947567T AT 97947567 T AT97947567 T AT 97947567T AT E315567 T1 ATE315567 T1 AT E315567T1
Authority
AT
Austria
Prior art keywords
integer ranging
adenosine receptor
formula
receptor antagonist
cooh
Prior art date
Application number
AT97947567T
Other languages
English (en)
Inventor
Constance F Neely
Original Assignee
Endacea Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Endacea Inc filed Critical Endacea Inc
Application granted granted Critical
Publication of ATE315567T1 publication Critical patent/ATE315567T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
AT97947567T 1996-11-19 1997-11-19 A-1-adenosin rezeptor antagoniste ATE315567T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/753,048 US5786360A (en) 1996-11-19 1996-11-19 A1 adenosine receptor antagonists

Publications (1)

Publication Number Publication Date
ATE315567T1 true ATE315567T1 (de) 2006-02-15

Family

ID=25028936

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97947567T ATE315567T1 (de) 1996-11-19 1997-11-19 A-1-adenosin rezeptor antagoniste

Country Status (8)

Country Link
US (5) US5786360A (de)
EP (2) EP1790651A1 (de)
JP (1) JP2001504491A (de)
AT (1) ATE315567T1 (de)
AU (1) AU5261598A (de)
CA (1) CA2264721C (de)
DE (1) DE69735108D1 (de)
WO (1) WO1998022465A1 (de)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5733916A (en) * 1995-03-24 1998-03-31 The Trustees Of The University Of Pennsylvania Prevention and treatment of ischemia-reperfusion and endotoxin-related injury using adenosine and purino receptor antagonists
US5958926A (en) * 1996-11-01 1999-09-28 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses
US5786360A (en) * 1996-11-19 1998-07-28 Link Technology Incorporated A1 adenosine receptor antagonists
JP3563938B2 (ja) 1997-09-29 2004-09-08 キヤノン株式会社 画像読取装置及びその制御方法
US6117445A (en) * 1998-01-28 2000-09-12 Link Technology Inc. Methods for the prevention and treatment of fibrosis and sclerosis
US6878716B1 (en) 1998-06-02 2005-04-12 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptor and uses thereof
AP1411A (en) 1998-06-02 2005-05-10 Osi Pharm Inc Pyrrolo[2,3d] pyrimidine compositions and their use.
US6686366B1 (en) 1998-06-02 2004-02-03 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
GB9819384D0 (en) * 1998-09-04 1998-10-28 Cerebrus Ltd Chemical compounds II
US7160890B2 (en) 1999-12-02 2007-01-09 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
PT1246623E (pt) 1999-12-02 2006-12-29 Osi Pharm Inc Compostos específicos para o receptor de adenosina a1,a2a e a3 e as suas utilizações
US6680322B2 (en) 1999-12-02 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
US6664252B2 (en) 1999-12-02 2003-12-16 Osi Pharmaceuticals, Inc. 4-aminopyrrolo[2,3-d]pyrimidine compounds specific to adenosine A2a receptor and uses thereof
US6680324B2 (en) 2000-12-01 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
US6673802B2 (en) 2000-12-01 2004-01-06 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
WO2003013543A1 (en) * 2001-08-08 2003-02-20 Genomed, Llc Treatment or prevention of acute renal failure
AU2002360436A1 (en) 2001-11-30 2003-06-17 Osi Pharmaceuticals, Inc. 2-aryl pyrrologpyrimidines for a1 and a3 receptors
EP1465634B1 (de) 2001-12-12 2014-10-22 The Government of the United States of America, as represented by the Secretary Department of Health and Human Services Verfahren zur verwendung adenosinrezeptorinhibitoren zur verstärkung der immunantwort und entzündung
CA2471059C (en) 2001-12-20 2011-04-26 Osi Pharmaceuticals, Inc. Pyrimidine a2b selective antagonist compounds, their synthesis and use
US20030229067A1 (en) 2001-12-20 2003-12-11 Arlindo Castelhano Pyrrolopyrimidine A2b selective antagonist compounds, their synthesis and use
JP2006518390A (ja) * 2003-02-19 2006-08-10 エンダシア，インコーポレイテッド Ａ１アデノシンレセプターアンタゴニスト
EP1636229A4 (de) * 2003-06-06 2008-07-30 Endacea Inc A1-adenosinrezeptorantagonisten
US20110282031A1 (en) * 2003-06-06 2011-11-17 Wilson Constance N A1 adenosine receptor diagnostic probes
CA2528367A1 (en) * 2003-06-09 2004-12-23 Endacea, Inc. A1 adenosine receptor antagonists
EP1863815A1 (de) * 2005-03-11 2007-12-12 Aderis Pharmaceuticals, Inc. Substituierte 9-alkyladenine und deren verwendung
US7696211B2 (en) * 2005-04-29 2010-04-13 Wilson Constance N Methods and pharmaceutical compositions for treating sepsis
US7795427B2 (en) * 2006-02-14 2010-09-14 New York University Methods for inhibiting osteoclast differentiation, formation, or function and for increasing bone mass
WO2007103970A2 (en) * 2006-03-07 2007-09-13 Endacea, Inc. Compositions and methods for treating respiratory disorders
US20090048155A1 (en) 2007-08-15 2009-02-19 Endacea, Inc. Methods for preventing and treating tissue injury and sepsis associated with Yersinia pestis infection
US9522916B2 (en) 2007-12-21 2016-12-20 Constance Neely Wilson A1 adenosine receptor antagonists
EP2274007B1 (de) 2008-03-10 2016-12-14 Cornell University Modulation der durchlässigkeit der blut-hirn-schranke
WO2011094208A2 (en) * 2010-01-26 2011-08-04 Endacea, Inc. Methods and pharmaceutical compositions for preventing and treating renal impairment
CA2810725A1 (en) 2010-09-15 2012-03-22 Constance Neely Wilson Methods of use and kit for measurement of lipopolysaccharide with a time resolved fluorescence based assay
EP3468960B1 (de) 2016-06-08 2022-03-23 GlaxoSmithKline Intellectual Property Development Limited Chemische verbindungen als atf4-pfad-hemmer
EP4279136A3 (de) 2016-12-03 2024-03-20 Juno Therapeutics, Inc. Verfahren zur festlegung der dosierung von car-t-zellen
US20190358262A1 (en) 2016-12-03 2019-11-28 Juno Therapeutics, Inc. Methods for modulation of car-t cells
KR20190098747A (ko) 2016-12-05 2019-08-22 주노 쎄러퓨티크스 인코퍼레이티드 입양 세포 치료법을 위한 조작된 세포의 제조방법
JP2020522489A (ja) 2017-06-02 2020-07-30 ジュノー セラピューティクス インコーポレイテッド 養子細胞療法を用いる処置のための製造物品および方法
WO2019006427A1 (en) 2017-06-29 2019-01-03 Juno Therapeutics, Inc. WALL MODEL FOR ASSESSING TOXICITIES ASSOCIATED WITH IMMUNOTHERAPIES
WO2019089858A2 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Methods of assessing or monitoring a response to a cell therapy
JP7256197B2 (ja) 2017-11-01 2023-04-11 ジュノー セラピューティクス インコーポレイテッド Ｂ細胞成熟抗原に特異的な抗体およびキメラ抗原受容体
MA50860A (fr) 2017-11-01 2020-09-09 Juno Therapeutics Inc Récepterus chimériques d'antigène contre l'antigène de maturation des cellules b et polynucleotides codants
EP3716980A1 (de) 2017-12-01 2020-10-07 Juno Therapeutics, Inc. Verfahren zur dosieren und modulierung von genetisch veränderten zellen
MA51184A (fr) 2017-12-15 2020-10-21 Juno Therapeutics Inc Molécules de liaison à l'anti-cct5 et procédés d'utilisation associés
US20210393690A1 (en) 2018-11-01 2021-12-23 Juno Therapeutics, Inc. Methods for treatment using chimeric antigen receptors specific for b-cell maturation antigen
EP3873937A2 (de) 2018-11-01 2021-09-08 Juno Therapeutics, Inc. Chimäre antigenrezeptoren spezifisch für g-protein-gekoppelte rezeptoren klasse c, gruppe 5, element d (gprc5d)
AU2019381827A1 (en) 2018-11-16 2021-06-10 Juno Therapeutics, Inc. Methods of dosing engineered T cells for the treatment of B cell malignancies
JP2022513685A (ja) 2018-11-30 2022-02-09 ジュノー セラピューティクス インコーポレイテッド 養子細胞療法を用いた処置のための方法
CN113365660A (zh) 2019-01-29 2021-09-07 朱诺治疗学股份有限公司 对受体酪氨酸激酶样孤儿受体1(ror1)具特异性的抗体及嵌合抗原受体
WO2021207689A2 (en) 2020-04-10 2021-10-14 Juno Therapeutics, Inc. Methods and uses related to cell therapy engineered with a chimeric antigen receptor targeting b-cell maturation antigen
WO2023250400A1 (en) 2022-06-22 2023-12-28 Juno Therapeutics, Inc. Treatment methods for second line therapy of cd19-targeted car t cells
WO2024031091A2 (en) 2022-08-05 2024-02-08 Juno Therapeutics, Inc. Chimeric antigen receptors specific for gprc5d and bcma

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3317533A (en) * 1967-05-02 Theophylline derivatives
BE636828A (de) *
US2887468A (en) * 1954-03-11 1959-05-19 Eastman Kodak Co Copolyesters of a glycol, a dicarboxylic acid and a hydroxy carboxylic acid
US2887486A (en) 1956-10-29 1959-05-19 S E Massengill Company Theophylline derivatives
US3317433A (en) 1958-10-23 1967-05-02 Ncr Co Heat rupturable capsules
DE1245383B (de) 1960-04-22 1967-07-27 Manuf De Produits Pharma A Chr Verfahren zur Herstellung von in 7-Stellung basisch substituierten 8-Benzyltheophyllinderivaten
GB947495A (en) 1960-04-22 1964-01-22 Manuf Prod Pharma New derivatives of dialkyl xanthines and the preparation thereof
US3031451A (en) 1960-07-21 1962-04-24 Endo Lab Salt of nicotinic acid
US3309271A (en) * 1963-08-30 1967-03-14 Manuf Prod Pharma Methods and composition for inducing choleresis
AU6889274A (en) * 1973-05-17 1975-11-20 Astra Laekemedel Ab Treatment of neurological disorders
US4092417A (en) 1976-12-08 1978-05-30 Johann A. Wulfing Theophylline salts of 5-methylisoxazole-3-carboxylic acid
DE2659241A1 (de) 1976-12-23 1978-07-06 Josef Dipl Chem Dr Rer N Klosa Xanthinol-orotat
SE7810947L (sv) 1978-10-20 1980-04-21 Draco Ab 3-alkylxanthines
EP0011399A1 (de) 1978-11-11 1980-05-28 FISONS plc N-Substituierte Theophylline, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Präparate
IT1195267B (it) 1980-04-15 1988-10-12 Abc Ist Biolog Chem Spa Derivati teofillinmetildiossolanici,procedimento per la loro preparazione e relative composizioni farmaceutiche
DE3120909C2 (de) 1980-06-05 1986-01-02 A. Christiaens S.A., Brüssel/Bruxelles Verfahren zur Herstellung von 7-(N-Äthyl-N-β-hydroxyäthylaminoäthyl)-8-benzyltheophyllin (Bamifyllin)
DE3028273A1 (de) 1980-07-25 1982-02-25 Fa. Dr. Willmar Schwabe, 7500 Karlsruhe Durch purinbasen substituierte 1.4;3.6-dianhydro-hexit-nitrate
US4769377A (en) 1983-02-18 1988-09-06 The Johns Hopkins University Adenosine receptor antagonists
US4612315A (en) * 1984-10-26 1986-09-16 The United States Of America As Represented By The Department Of Health And Human Services Biologically-active 1,3-dipropyl-8-phenylxanthine derivatives
US4696932A (en) * 1984-10-26 1987-09-29 The United States Of America As Represented By The Department Of Health And Human Services Biologically-active xanthine derivatives
US5248770A (en) * 1984-10-26 1993-09-28 The United States Of America, As Represented By The Department Of Health And Human Services Molecular probes for adenosine receptors
US4772607A (en) 1986-05-20 1988-09-20 Warner-Lambert Company Dialkenyl derivatives of xanthine, pharmaceutical compositions and methods of use therefor
IT1197516B (it) 1986-12-24 1988-11-30 Abc Ist Biolog Chem Spa Derivati teofillinmetilanici e teofillinmetilditianici procedimento per la loro preparazione e composizioni farmaceutiche che li comprendono
US4968672A (en) * 1987-01-02 1990-11-06 The United States Of America As Represented By The Department Of Health And Human Services Adenosine receptor prodrugs
US5066655A (en) 1987-04-24 1991-11-19 Whitby Research, Inc. N6-substituted 9-methyladenines: a new class of adenosine receptor antagonists
US5192740A (en) * 1987-12-21 1993-03-09 University Of Alberta Compositions and methods for improving cold tolerance in animals and humans
US5032593A (en) 1988-07-01 1991-07-16 Marion Merrell Dow Inc. Method of treating bronchoconstriction with 1,3-unsymmetrical straight chain alkyl-substituted 8-phenylxanthines
US5298508A (en) * 1988-07-19 1994-03-29 The United States Of America As Represented By The Department Of Health And Human Services Irreversible inhibitors of adenosine receptors
DE8817122U1 (de) * 1988-12-22 1993-02-04 Boehringer Ingelheim Kg, 6507 Ingelheim, De
JP2843634B2 (ja) * 1989-03-06 1999-01-06 協和醗酵工業株式会社 キサンチン誘導体
US4971972A (en) * 1989-03-23 1990-11-20 Schering Corporation Phosphodiesterase inhibitors having an optionally substituted purine derivative portion and a benzo- or cyclopenta-furan portion
US5256650A (en) 1989-03-29 1993-10-26 Merrell Dow Pharmaceuticals Inc. Selective adenosine receptor agents
IT1240843B (it) 1990-05-24 1993-12-17 Malesci Istituto Farmacobiologico Derivati xantinici 1-7 sostituiti ad attivita' antiasmatica, loro sali fisiologicamente accettabili, loro composizioni farmaceutiche e procedimento per la loro preparazione.
CA2061544A1 (en) * 1991-02-25 1992-08-26 Fumio Suzuki Xanthine compounds
US5208240A (en) * 1991-03-12 1993-05-04 Merrell Dow Pharmaceuticals Inc. 8-substituted purines as selective adenosine receptor agents
DE4129603A1 (de) * 1991-09-06 1993-03-11 Thomae Gmbh Dr K Kondensierte 5-gliedrige heterocyclen, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
EP0541120B1 (de) * 1991-11-08 1999-05-26 Kyowa Hakko Kogyo Co., Ltd. Xanthinderivate zur Behandlung der Demenz
DK0628311T3 (da) * 1992-07-08 2002-07-22 Kyowa Hakko Kogyo Kk Xanthinderivater som antidepressive midler
TW252044B (de) * 1992-08-10 1995-07-21 Boehringer Ingelheim Kg
US5340813A (en) * 1992-11-09 1994-08-23 Cell Therapeutics, Inc. Substituted aminoalkyl xanthine compounds
US5395836A (en) * 1993-04-07 1995-03-07 Kyowa Hakko Kogyo Co., Ltd. 8-tricycloalkyl xanthine derivatives
DE19535504A1 (de) * 1995-09-25 1997-03-27 Bayer Ag Substituierte Xanthine
US5786360A (en) * 1996-11-19 1998-07-28 Link Technology Incorporated A1 adenosine receptor antagonists

Also Published As

Publication number Publication date
CA2264721A1 (en) 1998-05-28
EP1790651A1 (de) 2007-05-30
US6489332B1 (en) 2002-12-03
US5786360A (en) 1998-07-28
WO1998022465A1 (en) 1998-05-28
DE69735108D1 (de) 2006-04-06
EP0946557A1 (de) 1999-10-06
US6495687B1 (en) 2002-12-17
EP0946557B1 (de) 2006-01-11
US20020082269A1 (en) 2002-06-27
CA2264721C (en) 2006-07-04
US6117998A (en) 2000-09-12
JP2001504491A (ja) 2001-04-03
AU5261598A (en) 1998-06-10

Similar Documents

Publication Publication Date Title
DE69735108D1 (de) A-1-adenosin rezeptor antagoniste
IL164967A0 (en) Use of estrogen antagonists and estrogen agonists in the preparation of medicament for inhibiting pathological conditions
GB2346878A (en) Preparation of 3-substituted adenines
GR3021581T3 (en) Vitamin D compounds and method of preparing these compounds.
DK0918776T3 (da) Totalsyntese af antitumor acylfulvener
PT806416E (pt) Derivados de huperzina a sua preparacao e utilizacao
TW427979B (en) A condensed piperidine compound
PT894787E (pt) Derivados de feniletanolaminotetralinocarboxilato 3,4-dissubstituidos
CO4960660A1 (es) Derivados de 5-aroil-pirrol-2-ilmetilareno, composiciones farmaceuticas que las contienen y metodos para la preparacion de estos compuestos
TR200002803T2 (tr) MRP1 inhibe etmek için yöntemler.
BR9901201A (pt) Composto de titanato
TR200002804T2 (tr) MRP1 inhibe etmek için yöntemler
FR2655039B1 (fr) Synthese des bromures de perfluoroalkyle.
TW222273B (de)
WO2004110379A3 (en) A1 adenosine receptor antagonists
GB9715709D0 (en) Novel compounds
DE69615814T2 (de) Uch-15-verbindungen
IT1272881B (it) Composti arilalchilenici

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties